Could DMT be beneficial in stroke recovery?

Could DMT be beneficial in stroke recovery?

Algernon Pharmaceuticals submits pre-IND meeting request for clinical research program in DMT for stroke
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

VANCOUVER, BC—Algernon Pharmaceuticals Inc. has announced the filing of a pre-Investigational New Drug (IND) meeting request with the FDA for the company’s investigation of AP-188 (N,N-Dimethyltryptamine, also known as DMT) for the treatment of stroke-related dysfunction. DMT is a known psychedelic compound that is part of the tryptamine family,

In the meeting request application, Algernon is asking for direction regarding the use of DMT as an adjunctive treatment with constraint-induced movement therapy (CIMT) for the treatment of upper-limb dysfunction in stroke patients. The company is also planning to file another pre-IND meeting request for the use of DMT as a treatment for acute stroke, when additional preclinical work has been completed.

CIMT is a form of physical therapy involving intensive training of a weaker limb, while restricting the use of a stronger limb. CIMT has demonstrated the ability to enhance recovery in the treatment of patients post-stroke. Algernon plans to evaluate whether adding DMT treatment to CIMT results in increased neuroplasticity, thereby enhancing the effects of physical therapy. 

Algernon’s decision to investigate DMT and move it into human trials for stroke is based on multiple preclinical studies demonstrating that DMT helps promote neurogenesis, as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.

One recently published preclinical study in an animal model for stroke has shown that rats treated with DMT recovered motor function quicker, and to a greater extent. The DMT-treated rats also exhibited lower lesion volumes when compared to control group animals that did not receive DMT.

Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage, and method of use claims for ischemic stroke. The company has also filed claims for combination therapy of DMT and CIMT. 

Algernon has awarded a contract to Dalton Pharma Services for the manufacture of the active pharmaceutical ingredient and finished product for the company’s formulation of DMT. The company also recently retained Charles River Laboratories to conduct its preclinical studies of DMT for the company’s stroke clinical research program, and has appointed Hammersmith Medicines Research Ltd. to conduct its DMT Phase 1 study.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue